November 28, 2018 / 6:37 PM / 12 days ago

FDA approves first biosimilar for Roche's cancer drug Rituxan

Nov 28 (Reuters) - The U.S. Food and Drug Administration said here on Wednesday it had approved Celltrion Inc's Truxima, the first biosimilar version of Roche Holding AG's cancer drug Rituxan. Celltrion entered into a partnership with Teva Pharmaceutical Industries in 2016 to commercialize the drug in United States and Canada. (Reporting by Manas Mishra in Bengaluru; Editing by Shailesh Kuber)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below